Anti-CD49b [31H4]

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Anti-CD49b [31H4]
• Alternate name: Integrin Subunit Alpha 2; Alpha 2 Subunit Of VLA-2 Receptor; Platelet Membrane Glycoprotein Ia; CD49 Antigen-Like Family Member B; Collagen Receptor; CD49B; GPIa; Very Late Activation Protein 2 Receptor; Alpha-2 Subunit; Human Platelet Alloantigen System; Platelet Glycoprotein GPIa; VLA-2 Subunit Alpha; CD49b Antigen; HPA-5; VLA-2; VLAA2; BR
• Research fields: Cell biology;Cell signaling and signal transduction;Immunology
• Clone: 31H4
• Tool sub type: Primary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Reactivity: Human
• Host: Mouse
• Application: ELISA ; FACS ; IP
• Description: CD49b also known as integrin alpha-2, VLA-2 subunit alpha or collogen receptor. CD49b is a 1181 amino acid Â?130 kDa single pass type-1 transmembrane glycoprotein which forms a heterodimer with integrin beta-1 and mediates the adhesion of platelets and other cell types to the extracellular matrix. Loss of the encoded protein is associated with bleeding disorder platelet-type 9. Antibodies against this protein are found in several immune disorders, including neonatal alloimmune thrombocytopenia.
• Immunogen: Purified human b1 integrin preparation from HT1080 fibrosarcoma cell extract.
• Isotype: IgG1
• Myeloma used: P3X63Ag8.653

Target Details

• Target: Integrin alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)
• Target background: CD49b also known as integrin alpha-2, VLA-2 subunit alpha or collogen receptor. CD49b is a 1181 amino acid 130 kDa single pass type-1 transmembrane glycoprotein which forms a heterodimer with integrin beta-1 and mediates the adhesion of platelets and other cell types to the extracellular matrix. Loss of the encoded protein is associated with bleeding disorder platelet-type 9. Antibodies against this protein are found in several immune disorders, including neonatal alloimmune thrombocytopenia.

Applications

• Application: ELISA ; FACS ; IP

Handling

• Format: Liquid
• Concentration: 1 mg/ml
• Unit size: 100 ug
• Storage buffer: PBS with 0.02% azide
• Storage conditions: -15° C to -25° C
• Shipping conditions: Dry ice

References

• Tanaka et al. 2012. Int J Oncol. 41(5):1837-44. PMID: 22923148.
• Differential sensitivity to paclitaxel-induced apoptosis and growth suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial adenocarcinoma cells.
• Tanaka et al. 2012. Oncol Rep. 28(1):330-6. PMID: 22552543.
• Impaired death-associated protein kinase-mediated survival signals in 5-fluorouracil-resistant human endometrial adenocarcinoma cells.
• Tanaka et al. 2010. Int J Oncol. 37(1):125-31. PMID: 20514404.
• Establishment and characterization of novel human uterine leiomyosarcoma cell lines.
• Tanaka et al. 2009. Int J Mol Med. 23(2):173-80. PMID: 19148540.
• Remodeling of the human endometrial epithelium is regulated by laminin and type IV collagen.
• Tanaka et al. 2008. Int J Mol Med. 22(5):581-7. PMID: 18949377.
• Autocrine/paracrine regulation of human endometrial stromal remodeling by laminin and type IV collagen.
• Tanaka et al. 2008. Oncol Rep. 20(1):13-23. PMID: 18575713.
• Experimental characterization of recurrent ovarian immature teratoma cells after optimal surgery.
• Tanaka et al. 2006. Oncol Rep. 15(4):939-47. PMID: 16525683.
• Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.
• Tanaka et al. 2005. Oncol Rep. 14(4):941-8. PMID: 16142355.
• Reduced radiosensitivity and increased CD40 expression in cyclophosphamide-resistant subclones established from human cervical squamous cell carcinoma cells.